{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:10:46Z","timestamp":1787357446824,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Governmental funding for healthcare research"},{"name":"S.R. Gorthon foundation"},{"name":"Hudfonden\/Welander-Finsen foundation"},{"name":"Research grants of the Southern health care region"},{"DOI":"10.13039\/100016409","name":"Gyllenstiernska Krapperup foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016409","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Inga and John Hain foundation for medical research"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["Dnr 2018-02786, Dnr 2022-00871"],"award-info":[{"award-number":["Dnr 2018-02786, Dnr 2022-00871"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["19 0458 Pj, 22 2105 Pj"],"award-info":[{"award-number":["19 0458 Pj, 22 2105 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["KAW 2022.0066"],"award-info":[{"award-number":["KAW 2022.0066"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016408","name":"G\u00f6ran Gustafssons Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.<\/jats:p>","DOI":"10.1007\/s00262-025-04269-9","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:21:55Z","timestamp":1766492515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modeling anti-tumor immune responses using patient-derived melanoma organoids"],"prefix":"10.1007","volume":"75","author":[{"given":"Kamila","family":"Kaminska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Karlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Harbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Pietras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Ekedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"4269_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P et al (2025) Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417. ([published Online First: 20240915])","journal-title":"N Engl J Med"},{"issue":"4","key":"4269_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN (2020) CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer 20(4):218\u2013232. https:\/\/doi.org\/10.1038\/s41568-019-0235-4. ([published Online First: 20200205])","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4269_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","volume":"6","author":"X Xiao","year":"2016","unstructured":"Xiao X, Lao XM, Chen MM et al (2016) PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov 6(5):546\u2013559. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1408","journal-title":"Cancer Discov"},{"issue":"12","key":"4269_CR4","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.4049\/jimmunol.1100274[publishedOnlineFirst:20110506]","volume":"186","author":"J Krempski","year":"2011","unstructured":"Krempski J, Karyampudi L, Behrens MD et al (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905\u20136913. https:\/\/doi.org\/10.4049\/jimmunol.1100274[publishedOnlineFirst:20110506]","journal-title":"J Immunol"},{"issue":"6","key":"4269_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH et al (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19(6):1189\u20131201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031","journal-title":"Cell Rep"},{"issue":"18","key":"4269_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA et al (2024) Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 391(18):1696\u20131708. https:\/\/doi.org\/10.1056\/NEJMoa2402604. ([published Online First: 20240602])","journal-title":"N Engl J Med"},{"issue":"7","key":"4269_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil P, de Bruijn M, Roelofsen LM et al (2021) An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med 27(7):1250\u20131261. https:\/\/doi.org\/10.1038\/s41591-021-01398-3. ([published Online First: 2021\/07\/10])","journal-title":"Nat Med"},{"issue":"2","key":"4269_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Aref AR, Lizotte PH et al (2018) Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov 8(2):196\u2013215. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0833","journal-title":"Cancer Discov"},{"issue":"43","key":"4269_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg6686","volume":"9","author":"L Sun","year":"2023","unstructured":"Sun L, Kang X, Ju H et al (2023) A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options. Sci Adv 9(43):eadg6686. https:\/\/doi.org\/10.1126\/sciadv.adg6686. ([published Online First: 20231027])","journal-title":"Sci Adv"},{"key":"4269_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104614","volume":"92","author":"L Ou","year":"2023","unstructured":"Ou L, Liu S, Wang H et al (2023) Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine 92:104614. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104614. ([published Online First: 20230523])","journal-title":"EBioMedicine"},{"issue":"2","key":"4269_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069694","volume":"14","author":"T Helkkula","year":"2024","unstructured":"Helkkula T, Christensen G, Ingvar C et al (2024) BioMEL: a translational research biobank of melanocytic lesions and melanoma. BMJ Open 14(2):e069694. https:\/\/doi.org\/10.1136\/bmjopen-2022-069694. ([published Online First: 20240202])","journal-title":"BMJ Open"},{"issue":"8","key":"4269_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101408","volume":"23","author":"AE Vilgelm","year":"2020","unstructured":"Vilgelm AE, Bergdorf K, Wolf M et al (2020) Fine-needle aspiration-based patient-derived cancer organoids. iScience 23(8):101408. https:\/\/doi.org\/10.1016\/j.isci.2020.101408. ([published Online First: 20200724])","journal-title":"iScience"},{"issue":"7","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J et al (2018) Organoid Modeling of the Tumor Immune Microenvironment. Cell 175(7):1972\u20131988. https:\/\/doi.org\/10.1016\/j.cell.2018.11.021","journal-title":"Cell"},{"issue":"9","key":"4269_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/nprot.2016.095","volume":"11","author":"M Pertea","year":"2016","unstructured":"Pertea M, Kim D, Pertea GM et al (2016) Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 11(9):1650\u20131667. https:\/\/doi.org\/10.1038\/nprot.2016.095. ([published Online First: 2016\/08\/26])","journal-title":"Nat Protoc"},{"issue":"11","key":"4269_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M et al (2016) VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 44(11):e108. https:\/\/doi.org\/10.1093\/nar\/gkw227. ([published Online First: 20160407])","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"4269_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164. https:\/\/doi.org\/10.1093\/nar\/gkq603. ([published Online First: 2010\/07\/06])","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4269_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin DA, Poslavsky S, Mitrophanov I et al (2015) MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 12(5):380\u2013381. https:\/\/doi.org\/10.1038\/nmeth.3364","journal-title":"Nat Methods"},{"issue":"11","key":"4269_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004503","volume":"11","author":"M Shugay","year":"2015","unstructured":"Shugay M, Bagaev DV, Turchaninova MA et al (2015) VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput Biol 11(11):e1004503. https:\/\/doi.org\/10.1371\/journal.pcbi.1004503. ([published Online First: 20151125])","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"4269_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J et al (2019) Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16(12):1289\u20131296. https:\/\/doi.org\/10.1038\/s41592-019-0619-0. ([published Online First: 20191118])","journal-title":"Nat Methods"},{"issue":"8046","key":"4269_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41586-024-08257-4","volume":"637","author":"A Elewaut","year":"2025","unstructured":"Elewaut A, Estivill G, Bayerl F et al (2025) Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637(8046):716\u2013725. https:\/\/doi.org\/10.1038\/s41586-024-08257-4. ([published Online First: 20241127])","journal-title":"Nature"},{"issue":"1","key":"4269_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, Pedri D, Landeloos E et al (2024) A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell 187(1):166\u2013183. https:\/\/doi.org\/10.1016\/j.cell.2023.11.037","journal-title":"Cell"},{"issue":"1","key":"4269_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister C, Satija R (2019) Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20(1):296. https:\/\/doi.org\/10.1186\/s13059-019-1874-1. ([published Online First: 20191223])","journal-title":"Genome Biol"},{"issue":"5","key":"4269_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P et al (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411\u2013420. https:\/\/doi.org\/10.1038\/nbt.4096. ([published Online First: 20180402])","journal-title":"Nat Biotechnol"},{"issue":"7791","key":"4269_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561\u2013565. https:\/\/doi.org\/10.1038\/s41586-019-1914-8. ([published Online First: 2020\/01\/17])","journal-title":"Nature"},{"issue":"4","key":"4269_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V et al (2017) Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171(4):934\u2013949. https:\/\/doi.org\/10.1016\/j.cell.2017.09.028","journal-title":"Cell"},{"issue":"6257","key":"4269_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207\u2013211. https:\/\/doi.org\/10.1126\/science.aad0095. ([published Online First: 2015\/09\/12])","journal-title":"Science"},{"issue":"7","key":"4269_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nmeth.3407","volume":"12","author":"AD Ewing","year":"2015","unstructured":"Ewing AD, Houlahan KE, Hu Y et al (2015) Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods 12(7):623\u2013630. https:\/\/doi.org\/10.1038\/nmeth.3407. ([published Online First: 2015\/05\/20])","journal-title":"Nat Methods"},{"issue":"2","key":"4269_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003[publishedOnlineFirst:2019\/02\/13]","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM et al (2019) Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer Cell 35(2):238\u2013255. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003[publishedOnlineFirst:2019\/02\/13]","journal-title":"Cancer Cell"},{"issue":"7930","key":"4269_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras P, Bordeu I, Pozniak J et al (2022) A cellular hierarchy in melanoma uncouples growth and metastasis. Nature 610(7930):190\u2013198. https:\/\/doi.org\/10.1038\/s41586-022-05242-7. ([published Online First: 20220921])","journal-title":"Nature"},{"issue":"6","key":"4269_CR30","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/pcmr.13189","volume":"37","author":"M Hu","year":"2024","unstructured":"Hu M, Coleman S, Judson-Torres RL et al (2024) The classification of melanocytic gene signatures. Pigment Cell Melanoma Res 37(6):854\u2013863. https:\/\/doi.org\/10.1111\/pcmr.13189. ([published Online First: 20240728])","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"4269_CR31","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044[publishedOnlineFirst:2015\/06\/20]","volume":"161","author":"TCGA","year":"2015","unstructured":"TCGA (2015) Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044[publishedOnlineFirst:2015\/06\/20]","journal-title":"Cell"},{"issue":"6","key":"4269_CR32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009[publishedOnlineFirst:20180809]","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F et al (2018) Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell 174(6):1586\u20131598. https:\/\/doi.org\/10.1016\/j.cell.2018.07.009[publishedOnlineFirst:20180809]","journal-title":"Cell"},{"issue":"12","key":"4269_CR33","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D et al (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916\u20131927. https:\/\/doi.org\/10.1038\/s41591-019-0654-5","journal-title":"Nat Med"},{"issue":"48","key":"4269_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp4670","volume":"10","author":"G Tarantino","year":"2024","unstructured":"Tarantino G, Ricker CA, Wang A et al (2024) Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. Sci Adv 10(48):eadp4670. https:\/\/doi.org\/10.1126\/sciadv.adp4670","journal-title":"Sci Adv"},{"issue":"1","key":"4269_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5","journal-title":"Genome Biol"},{"issue":"48","key":"4269_CR36","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger S, Luke JJ, Bao R et al (2016) Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A 113(48):E7759\u2013E7768. https:\/\/doi.org\/10.1073\/pnas.1609376113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7791","key":"4269_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549\u2013555. https:\/\/doi.org\/10.1038\/s41586-019-1922-8. ([published Online First: 2020\/01\/17])","journal-title":"Nature"},{"issue":"9","key":"4269_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958. ([published Online First: 2016\/07\/20])","journal-title":"N Engl J Med"},{"issue":"1","key":"4269_CR39","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH et al (2017) Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 8(1):1136. https:\/\/doi.org\/10.1038\/s41467-017-01062-w","journal-title":"Nat Commun"},{"issue":"1","key":"4269_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47425-y","volume":"15","author":"M Lauss","year":"2024","unstructured":"Lauss M, Phung B, Borch TH et al (2024) Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun 15(1):3075. https:\/\/doi.org\/10.1038\/s41467-024-47425-y. ([published Online First: 20240409])","journal-title":"Nat Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04269-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T01:02:38Z","timestamp":1766538158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04269-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04269-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7486809\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"24"}}